ArticleAnnals of cardiac anaesthesia2026
Role of Non-catecholamines Vasopressors in the Management of Vasoplegic Syndrome after Cardiopulmonary Bypass: A Scoping Review.
Article in Annals of cardiac anaesthesia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vasoplegic syndrome is a life-threatening condition characterized by uncontrolled peripheral vasodilation, leading to profound arterial hypotension. Treatments include catecholamines, vasopressin, methylene blue (MB), hydroxocobalamin, angiotensin II, and ascorbic acid. We developed a scoping review protocol according to the Joanna Briggs Institute methodology and searched PubMed, PubMed Central, Scopus, and Cochrane Library electronic databases. A total of 23 records were included in this scoping review, out of which 13 were original research studies, seven were reviews, and three were case studies. In these studies, vasopressin, MB, hydroxocobalamin, angiotensin II, and ascorbic acid were used for vasoplegic syndrome. Vasopressin, MB, hydroxocobalamin, angiotensin II, and ascorbic acid showed rapid restoration of hemodynamics and decreased vasopressor requirement. Non-catecholamine drugs such as vasopressin, angiotensin II, MB, and hydroxocobalamin appear to be promising drugs for the treatment of patients with post-cardiac surgery vasoplegic syndrome. It is demonstrated to be effective in raising blood pressure in such patients, but these agents should be used cautiously due to their associated adverse effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.